X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs GLENMARK PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. GLENMARK PHARMA FRESENIUS KABI ONCO./
GLENMARK PHARMA
 
P/E (TTM) x 22.1 12.2 181.4% View Chart
P/BV x 3.1 3.2 96.6% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   GLENMARK PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
GLENMARK PHARMA
Mar-17
FRESENIUS KABI ONCO./
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs176993 17.7%   
Low Rs79729 10.8%   
Sales per share (Unadj.) Rs37.7325.5 11.6%  
Earnings per share (Unadj.) Rs5.139.3 13.0%  
Cash flow per share (Unadj.) Rs6.748.7 13.8%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs42.5159.2 26.7%  
Shares outstanding (eoy) m158.23282.17 56.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.6 127.6%   
Avg P/E ratio x25.021.9 114.0%  
P/CF ratio (eoy) x18.917.7 107.0%  
Price / Book Value ratio x3.05.4 55.3%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m20,135242,991 8.3%   
No. of employees `0001.213.0 8.9%   
Total wages/salary Rs m70316,408 4.3%   
Avg. sales/employee Rs Th5,176.27,083.9 73.1%   
Avg. wages/employee Rs Th610.41,265.4 48.2%   
Avg. net profit/employee Rs Th699.6855.1 81.8%   
INCOME DATA
Net Sales Rs m5,96391,857 6.5%  
Other income Rs m18374 4.8%   
Total revenues Rs m5,98192,230 6.5%   
Gross profit Rs m1,43020,367 7.0%  
Depreciation Rs m2582,644 9.8%   
Interest Rs m-262,373 -1.1%   
Profit before tax Rs m1,21615,724 7.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-68-810 8.4%   
Tax Rs m3423,827 8.9%   
Profit after tax Rs m80611,088 7.3%  
Gross profit margin %24.022.2 108.2%  
Effective tax rate %28.124.3 115.6%   
Net profit margin %13.512.1 112.0%  
BALANCE SHEET DATA
Current assets Rs m5,10268,746 7.4%   
Current liabilities Rs m2,38527,027 8.8%   
Net working cap to sales %45.645.4 100.3%  
Current ratio x2.12.5 84.1%  
Inventory Days Days15085 176.5%  
Debtors Days Days11396 118.6%  
Net fixed assets Rs m5,14824,132 21.3%   
Share capital Rs m158282 56.1%   
"Free" reserves Rs m6,55644,643 14.7%   
Net worth Rs m6,73244,925 15.0%   
Long term debt Rs m95245,363 2.1%   
Total assets Rs m10,388117,639 8.8%  
Interest coverage x-45.87.6 -600.3%   
Debt to equity ratio x0.11.0 14.0%  
Sales to assets ratio x0.60.8 73.5%   
Return on assets %7.511.4 65.6%  
Return on equity %12.024.7 48.5%  
Return on capital %14.619.1 76.3%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29856,152 9.4%   
Fx outflow Rs m1,7728,084 21.9%   
Net fx Rs m3,52548,068 7.3%   
CASH FLOW
From Operations Rs m1,2746,574 19.4%  
From Investments Rs m-1,204-7,124 16.9%  
From Financial Activity Rs m-1965,432 -3.6%  
Net Cashflow Rs m-1261,992 -6.3%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 6.9 4.3%  
FIIs % 9.6 34.4 27.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   42,599 56,727 75.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS